Siglec-6 Is a Novel Target for CAR T-Cell Therapy in Acute Myeloid Leukemia (AML)

Researchers introduced sialic-acid-binding immunoglobulin-like lectin (Siglec)-6 as a novel target for CAR T-cells in acute myeloid leukemia (AML) and found that Siglec-6 was prevalently expressed on AML cell lines and primary AML blasts, including the subpopulation of AML stem cells.